Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 755-762

  Rabin, Ltnda ^a,c   Hincenbergs, Mara ^a,c   Moreno, Mary Beth ^a,c   Warren, Suzette ^a,c   Linquist, Valerie ^a,c   Datema, Roelf ^a   Charpiot, Brigitte ^a   Seifert, Jan ^a   Kaneshima, Hideto ^a   McCune, Joseph M ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENE;

EID: 9044240866     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.755     Document Type: Article

References (31)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986 Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59:28-4-291.
2. Aldrovandi, G., G. Feuer, L. Gao, B. Jamieson, M. Kristeva, I. S. Chen, and J. A. Zack. 1993. The SCID-hu mouse as a model for HIV-1 infection. Nature (London) 363:732-736
3. Bonyhadi, M. L., L. Rabin, S. Salimi. D. A. Brown, J. Kosek, J. M. McCune, and H. Kaneshima. 1993. HIV induces thymus depletion in vivo. Nature (London) 363:728-732.
4. Cheeseman, S. H., and The ACTG 164/168 Study Team. 1992. Nevirapine (NVP) alone and in combination with zidovudine, abstr M.B0053. In Abstracts of the VIII International Conference on AIDS. World Congress. CONGREX Holland B V., Amsterdam.
5. Cheeseman, S. H., S. E. Hattox, M. M. McLaughLin, R. A. Koup, C. Andrews, C. A. Bova, J. W. Pav, T. Roy, J. L. Sullivan, and J. J. Keirns. 1993. Pharmacokinetics of nevirapine. initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37:178-182.
6. Datema, R., L. Rabin, M. Hincenbergs, M. B. Moreno, S. Warren, V. Linquist, B. Rosenwirth, J. Seifert, and J. M. McCune. 1996. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100). an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40:750-754.
7. De Clercq, E. 1993. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:229-258.
8. DiMasi, J. A., R. W. Hansen, II. G. Grabowski, and L. Lasagna. 1991. Cost of innovation in the pharmaceutical industry J. Health Econ. 10:107-142.
9. Flexner, C., D. A. Barditch-Crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty, and P. Lietman. 1991. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother. 35:2544-2550.
10. Gao, W. Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine. and dideoxyinosme in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-2333.
11. Hargrave, K. D., J. R. Proudfoot, K. G. Grozinger, E. Cullen, S. R. Kapadia, U. R. Patel, V. U. Fuchs, S. C. Mauldin, J. Vitous, M. L. Behnke, J. M. Klunder, K. Pal, J. W. Skiles, D. W. McNeil, J. M. Rose, G. C. Chow, M. T. Skoog, J. C. Wu, G. Schmidt, W. W. Engel, W. G. Eberlein, T. D. Saboe, S. J. Campbell, A. S. Rosenthal, and J. Adams. 1991 Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem. 34:2231-2241.
12. Havlir, D., and The ACTG 164 and 168 Study Teams. 1993. Antiviral activity of nevirapine at 400 mg in p24 antigen positive adults, abstr. WS-B26-1, p. 69. In Abstracts of the IXth International Conference on AIDS, mwm-Vermittlung, Berlin
13. Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, M. Lamson, and D. D. Richman. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:537-545
14. Kaneshima, H., L. Su, M. Bonyhadi, R. Conner, D. Ho, and J. M. McCune. 1994. Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol. 68:8188-8192
15. Kaneshima, H., C.-C. Shih, R. Namikawa, L. Rabin, H. Outzen, S. Machado, and J. M. McCune. 1991 HIV infection of human lymph nodes in the SCID-hu mouse: a useful small animal model for testing the efficacy of antiviral compounds Proc Natl Acad. Sci USA 88:4523-4527.
16. Koyanagi, Y., S. Miles, R. T. Mitsuyasu, J. E. Merrill, H. V. Vinters, and I. S. Chen. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropism Science 236:819-822.
17. Krowka, J., S. Sarin, R. Namikawa, J. M. McCune, and H. Kaneshima. 1991. The human T cells of the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol. 145:3751-3756.
18. McCune, J. M. 1990. The rational design of animal models for HIV infection. Semin. Virol. 1:229-235.
19. McCune, J. M., R. Namikawa, H. Kaneshima, L. D. Shultz, M. Lieberman, and I. L. Weissman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.
20. McCune, J. M., R. Namikawa, C.-C. Shih, L. Rabin, and H. Kaneshima. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:564-566.
21. Namikawa, R., H. Kaneshima, M. Lieberman, I. L. Weissman, and J. M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science 242: 1684-1687.
22. Namikawa, R., K. N. Weilbaecher, H. Kaneshima, E. J. Yee, and J. M. McCune. 1990. Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 172:1055-1063.
23. Norman, M. H., D. J. Minick, and G. E. Martin. 1993 Structural elucidation of an oxazolo[5,4-b]pyridine. an alternative cyclization product related to nevirapine. J. Heterocyclic Chem. 30:771-775.
24. Rabin, L.. M. Hincenbergs, M. B. Moreno, S. Warren, V. Linquist, R. Datema, B. Charpiot J. Seifert, H. Kaneshima, and J. M. McCune. Unpublished data.
25. Shelton, J. J., A. M. O'Donnell, and G. O. Morse. 1992. Didanosine. Ann. Pharmacother. 26:660-670.
26. Stanley, S. K., J. M. McCune, H. Kaneshima, J. S. Justement, M. Sullivan, E. Boone, M. Baseler, J. Adelsberger, M. Bonyhadi, J. Orenstein, C. F. Fox, and A. S. Fauci. 1993. Human immunodeficiency virus (HIV)-related damage to the human thymus: HIV infects thymocyte subsets and thymic epithelial cells in human thymus xenografts in the SCID-hu mouse. J. Exp. Med. 178:1151-1163.
27. Su, L., H. Kaneshima, M. Bonyhadi, S. Salimi, D. Kraft, L. Rabin, and J. M. McCune. 1995 HIV-1 induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo. Immunity 2:25-36.
28. Vandekerckhove, B. A. E., R. Baccala, D. Jones, D. H. Kono, A. N. Theofilopoulos, and M. G. Roncarolo. 1992. Thymic selection of human T cell receptor V beta repertoire in SCID-hu mice. J. Exp. Med. 176:1619-1624.
29. Vandekerckhove, B. A. E., J. F. Krowka, J. M. McCune, J. E. de Vries, H. Spits, and M. G. Roncarolo. 1991. Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J. Immunol. 146:4173-4179.
30. Williams, L. M., and M. W. Cloyd. 1991. Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology 184:723-728.
31. Witvrouw, M., R. Pauwels, A.-M. Vandamme, D. Schols, D. Reymen, N. Yamamoto, J. Desmyter, and E. DeClercq. 1992 Cell-type specific antihuman deficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob. Agents Chemother. 36:2628-2033.